DOI: 10.1001/jamaoto.2026.1659 ISSN: 2168-6181

Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck Cancer

Christopher W. Noel, Jennifer Guo, David Forner, Alex O. Esemezie, Lauren E. Miller, Shao Hui Huang, Jonathan C. Irish, John R. de Almeida, Ambika Parmar, Rui Fu, Antoine Eskander
Show PDF Cite

This economic evaluation evaluates the cost-effectiveness of perioperative pembrolizumab plus standard of care (SOC) for the treatment of locally advanced head and neck squamous cell carcinoma compared with SOC alone using Canada as a case study.

More from our Archive